ABBV - Conference and earnings call announcements

NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. Management will participate in a fireside chat at 9:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key th

NORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026. Management will participate in a fireside chat at 1:20 p.m. Central Time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therape

NORTH CHICAGO, Ill., March 3, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a fireside chat at 10:20 a.m. Central Time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therape

NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeuti

NORTH CHICAGO, Ill., Jan. 5, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key thera

NORTH CHICAGO, Ill., Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate in a fireside chat at 7:30 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key

NORTH CHICAGO, Ill., Sept. 2, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. Management will participate in a fireside chat at 9:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across sever

Select Business Owners Will Receive Access to Coaching, Mentorship, and Community During Exclusive 12-Week Virtual "Boostcamp"Additionally, 20 Entrepreneurs Will Each Receive a $20,000 Grant from BOTOX® CosmeticIRVINE, Calif., July 22, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the 2025 class of entrepreneurs who will participate in The Confidence Project: Empowering Women Entrepreneurs. This initiative, led by BOTOX® Cosmetic, is aimed at closing the Confidence Gap and accelerating business growth for select entrepreneurs from across the country. This year's participants were selected from a pool of applicants representing a wide range of indust

The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is committed to supporting the migraine community beyond treatment.Migraine affects productivity and career growth—up to 90% of people with migraine report it interferes with their ability to function at work, highlighting the need for meaningful support beyond treatment.NORTH CHICAGO, Ill., June 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the second annual AbbVie Migraine Career Catalyst Awar

NORTH CHICAGO, Ill., June 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025. Management will participate in a fireside chat at 10:20 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several ke

NORTH CHICAGO, Ill., May 6, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key ther

BOTOX® Cosmetic Will Provide 250 Entrepreneurs with Access to New Resources and Opportunities and Will Award 20 Grants Worth $20,000 Each to Support Business Goals.By 2030, BOTOX® Cosmetic Pledges to Empower 50,000 Entrepreneurs, Helping to Close the Confidence Gap.IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced BOTOX® Cosmetic's continued commitment to closing the Confidence Gap with the introduction of The Confidence Project: Empowering Women Entrepreneurs. The one & only BOTOX® Cosmetic invites business owners to apply for this year's program starting today through May 9, 2025, at 11:59pm PT.

NORTH CHICAGO, Ill., March 4, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate in a fireside chat at 7:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therap

NORTH CHICAGO, Ill., Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025. Management will participate in a fireside chat at 8:10 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key thera

NORTH CHICAGO, Ill., Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therap

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced participation in a live investor webinar (the "Webinar") focused on a discussion of Duchenne muscular dystrophy ("DMD") by Key Opinion Leaders ("KOLs") in the space. Registration for the event is available at the following link: https://propthink.clickmeeting.com/duchenne-kol-investor-call/register The live event, hosted by PropThink Digital Conferences (the "Host"), will take place on Wednesday, December 4, 2024, at 2:00 pm ET, and focus on three crucial to

NORTH CHICAGO, Ill., Nov. 25, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024. Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., executive vice president, Research & Development and chief scientific officer, will present at 9:15 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver

NORTH CHICAGO, Ill., June 3, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 9:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that

NORTH CHICAGO, Ill., May 6, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 12:40 p.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. Ab

NORTH CHICAGO, Ill., March 7, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 8:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

NORTH CHICAGO, Ill., Feb. 27, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 8:10 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About A

NORTH CHICAGO, Ill., Jan. 2, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D. senior vice president, development and regulatory affairs and chief medical officer, will present at 10:15 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be availabl

NORTH CHICAGO, Ill., Sept. 6, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. Robert A. Michael, president and chief operating officer, Scott Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 9:50 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be avail

– AbbVie's 2023 Week of Possibilities brings more than 14,000 employees together to participate in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact– Week of Possibilities is AbbVie's annual, global volunteering program that unites employees around the world with a single purpose: to give back to local communities through volunteering  NORTH CHICAGO, Ill., June 26, 2023 /PRNewswire/ -- AbbVie kicks off its eighth Week of Possibilities today with more than 14,000 employees volunteering in more than 50 countries and territories to serve local communities around the world. The annual volunteer initiative is aligne

NORTH CHICAGO, Ill., June 6, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. Robert A. Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 10:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver inn

NORTH CHICAGO, Ill., May 2, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 10:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About

NORTH CHICAGO, Ill., March. 8, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 12:35 p.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About Abb

NORTH CHICAGO, Ill., Feb. 28, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 8:10 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVi

NORTH CHICAGO, Ill., Jan. 3, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Richard A. Gonzalez, chairman and chief executive officer, will present at 5:00 p.m. CT. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key ther

NORTH CHICAGO, Ill., Nov. 23, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Tom Hudson senior vice president, R&D and chief scientific officer, will present at 9:55 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to

NORTH CHICAGO, Ill., Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Tom Hudson senior vice president, R&D and chief scientific officer, will present at 8:30 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to disco

NORTH CHICAGO, Ill., Nov. 9, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the 4th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Neil Gallagher, vice president development and chief medical officer will present virtually at 10:30 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission

NEARLY 20,000 PEOPLE RESPONDED TO AN OPEN CASTING CALL FOR A CHANCE TO BE FEATURED IN THE UPCOMING CAMPAIGN FOR THE NUMBER ONE SELLING PRODUCT OF ITS KIND IRVINE, Calif., Sept. 13, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX® Cosmetic 'See Yourself' campaign. After receiving nearly 20,000 submissions to its first-ever open casting call, BOTOX® Cosmetic, the #1 selling product of its kind1, is creating a content series that captures inspiring and intimate accounts of people speaking candidly about how they s

NORTH CHICAGO, Ill., Sept. 7, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Rob Michael, vice chairman and president, Jeff Stewart, executive vice president, commercial operations, and Neil Gallagher, vice president development and chief medical officer will present at 9:35 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious healt

NORTH CHICAGO, Ill., May 25, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022. Richard A. Gonzalez, chairman and chief executive officer, will present at 10:00 a.m. Central Time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across s

- Combines Plexium's novel TPD technology platform with AbbVie's extensive neuroscience expertise - SAN DIEGO, April 28, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium) and AbbVie (NYSE:ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions. This collaboration combines AbbVie's extensive neuroscience capabilities with Plexium's comprehensive TPD platform that enables the discovery of novel therapies toward historically challenging drug targets.  "Our partnership with AbbVie allows us to strengthen our leadership position in Targeted Protein Degradation and broaden our best-in-cla

Iconic Brand Was The First Product Of Its Kind To Receive U.S. Food And Drug Administration Approval In 2002 For Aesthetic Use And Is Honoring This Milestone By Celebrating Its Loyal Patients And Providers IRVINE, Calif., April 13, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the celebration of a milestone moment for BOTOX® Cosmetic (onabotulinumtoxinA). April 15, 2022, will mark 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between your eyebrows.1 It was the first product of its kind and has since received two additional aesthetic indi

NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2021. Robert A. Michael, vice chairman, finance and commercial operations and chief financial officer, Michael E. Severino, M.D., vice chairman and president, and Jeffrey R. Stewart, executive vice president, chief commercial officer, will present virtually at 11:50 a.m. Central Time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver inno

NORTH CHICAGO, Ill., Jan. 4, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. Members of AbbVie's executive leadership team will present virtually at 2:45 p.m. CT, including Robert A. Michael, vice chairman, finance and commercial operations and chief financial officer, Michael E. Severino, M.D., vice chairman and president, and Jeffrey R. Stewart, executive vice president, chief commercial officer. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About Ab

NORTH CHICAGO, Ill., Dec. 9, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE:ABBV) company, today announced that VUITY™ (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies nationwide. Presbyopia, or age-related blurry near vision, can be diagnosed through a basic eye exam by an eye doctor (optometrist or ophthalmologist) and is a common and progressive eye condition that affects 128 million Americans, or nearly half of the U.S. adult population. Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/896985

NORTH CHICAGO, Ill., Nov. 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI®, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. The submission is supported by three pivotal Phase 3 studies, ADVANCE, MOTIVATE and FORTIFY.1,2 "Patients with moderate to severe Crohn's disease live with challenging symptoms

NORTH CHICAGO, Ill., Nov. 23, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 2, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 11:10 a.m. CT. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve seri

NORTH CHICAGO, Ill., Nov. 23, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference on Wednesday, December 1, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 9:30 a.m. CT. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve se

NORTH CHICAGO, Ill., Nov. 18, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the publication of results from a new literature review in Advances in Therapy. The literature review reported that achieving clinical remission in rheumatoid arthritis (RA) is likely to be associated with economic benefits, such as reduced direct and indirect disease-related medical costs compared with other disease activity levels.1 "People with rheumatoid arthritis not only experience a significant physical and emotional burden, but this chronic, progressive disease is also associated with a substantial financial impact," said Sepideh F. Varon, Vice President, Health Economics and Outcomes Research, Immu

NORTH CHICAGO, Ill., Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 8:30 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious hea

IRVINE, Calif., Oct. 11, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to breast health, awareness, restoration, and research in support of breast cancer awareness month. For the month of October and into 2022, Allergan Aesthetics , The Power of You campaign will kick off a new series of initiatives and partnerships to support organizations creating a measurable impact in the fight against breast cancer.   The Power of You supports women as they navigate breast cancer. The campaign showcases real women and their authentic stories of courage, strength, and community as they embark on their journeys ahead. "Allergan Aesthetics is

NORTH CHICAGO, Ill., Sept. 20, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. The submission is supported by safety and efficacy data from three Phase 3 studies – ADVANCE, MOTIVATE and FORTIFY. "While there have been advancements in care, many people with Crohn's disease do not achieve lasting remission," said Tom Hudson, senior vice president of resear

NORTH CHICAGO, Ill., Sept. 9, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021. Richard A. Gonzalez, chairman and chief executive officer, Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 9:15 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to develop and commercialize Caraway’s small molecule therapeutics targeting TMEM175, a potassium ion channel critical to lysosomal function implicated in both Parkinson’s disease (PD) and other neurodegenerative disorders. TMEM175 is a compelling target with strong genetic support. Loss of function mutations in TMEM175 are associated with reduced lysosomal efficiency in a subpopulation of PD patients, that can manifest as earlier age of disease onset or elevated risk of dementia relative to idiopathic PD. Under this collaboration, Carawa

NORTH CHICAGO, Ill., June 2, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 8:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines th

NORTH CHICAGO, Ill., May 26, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in Bernstein's 37th Annual Strategic Decisions Conference on Wednesday, June 2, 2021. Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive vice president and chief financial officer, will present virtually at 2:30 p.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges

NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- Late-breaking data analyses presented by AbbVie (NYSE:ABBV) at Digestive Disease Week® (DDW) Virtual Conference 2021 showed significantly greater proportions of patients with moderately to severely active Crohn's disease treated with both doses of investigational risankizumab (600 mg or 1200 mg) met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo (p<0.001 for each) in two Phase 3 induction studies.1 This is the first presentation of data from these two studies, ADVANCE and MOTIVATE, following the announcement of top-line data earlier this year. The ADVANCE study included patients with past

NORTH CHICAGO, Ill., May 20, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 11:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve ser

NORTH CHICAGO, Ill., April 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. "We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Our new products are delivering impressive performance and we are on the cusp of potential commercial approvals for more than a dozen new products or indications over the next two years – including five expected approvals in 2021." First-Quarter Results Worldwide GAAP net revenues were $13.010 billion, an i

NORTH CHICAGO, Ill., Feb. 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 10:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve

NORTH CHICAGO, Ill., Feb. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 9:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines

NORTH CHICAGO, Ill., Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in pati

NORTH CHICAGO, Ill., Jan. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive leadership team will present virtually at 3:30 p.m. Central time, including Richard A. Gonzalez, chairman of the board and chief executive officer, Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition o